澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

新冠治療股

856.977

+8.6111.02%

漲家數：9

跌家數：1

平家數：22

市盈率：- -

高：857.029

開：855.760

低：854.289

收：848.365

成交量：662.21萬

成交額：1,337.88萬

市值：2,166.96億

流通市值：1,716.32億

資料載入中...

總覽新聞資訊

3M公司(MMM)股票3月23日收盤上漲3.81%：投資者必看的核心信息

TradingKey中文

CSL 表示出血性疾病基因療法全球缺貨

CSL有限公司正與監管機構協作制定策略確保Hemgenix持續穩定供應

今日優惠-合併與收購

CSL Seqirus將攜手長期合作伙伴Sinergium Biotech 供應差異化流感疫苗組合

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK7501/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"BK7501","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","market":"AU","secType":"PLATE","nameCN":"新冠治療股","latestPrice":856.9767,"timestamp":1774393238213,"preClose":848.36536,"halted":0,"volume":6622081,"delay":0,"changeRate":0.01015,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":8.611328,"latestTime":"03-25 10:00:38 AEDT","open":855.76,"high":857.02924,"low":854.289,"amount":13378824,"amplitude":0.00323,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1774414800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774393200000,1774414800000]],"turnoverRate":0.000461,"increases":15,"decrements":4,"flats":13,"marketCap":216696043359.5,"floatMarketCap":171632189631.08594},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","high":857.02924,"amplitude":0.00323,"preClose":848.36536,"low":854.289,"latestPrice":856.9767,"volume":6622081,"delay":0,"open":855.76,"prevYearClose":900.1661,"prevWeekClose":840.804,"prevMonthClose":875.89,"prevQuarterClose":900.166,"fiveDayClose":844.007,"twentyDayClose":874.337,"sixtyDayClose":901.913,"secType":"PLATE","market":"AU","turnoverRate":0.000461,"marketCap":216696043359.5,"floatMarketCap":171632189631.08594,"timestamp":1774393238213,"nameCN":"新冠治療股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7501\",,,,undefined,":{"bkCode":"BK7501","up":9,"down":1,"flat":22},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7501\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621846180","title":"3M公司(MMM)股票3月23日收盤上漲3.81%：投資者必看的核心信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2621846180","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621846180?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 04:16","pubTimestamp":1774296971,"startTime":"0","endTime":"0","summary":"• 3M与贝恩资本合作，以19.5亿美元收购Madison Fire & Rescue。\n• 3M的目标是到2026年实现3%的内生性增长，到2027年营业利润率达到25%。\n• 近期的股息上调和分析师的正面评论提振了投资者信心。","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/Market-Movers/261711176-market-movers-mmm-20260323","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002232.USD","LU1093756168.USD","IE000M9KFDE8.USD","BK4585","BK4533","BK4534","LU0787776722.HKD","LU0683600562.USD","BK7040","LU1064131342.USD","LU1894683264.USD","BK4206","SG9999002224.SGD","LU1894683348.USD","MMM","BK7501","LU1093756325.SGD","MMM.AU","BK4512","BK7049","LU1988902786.USD","LU2264538146.SGD","BK4588"],"gpt_icon":0},{"id":"2620471351","title":"CSL 表示出血性疾病基因療法全球缺貨","url":"https://stock-news.laohu8.com/highlight/detail?id=2620471351","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620471351?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 00:37","pubTimestamp":1773765430,"startTime":"0","endTime":"0","summary":"路透3月17日 - 澳大利亚CSLCSL.AX公司表示，其出血性疾病基因疗法Hemgenix面临暂时性全球缺货，这将推迟该药物在已上市国家的部分患者的治疗。医生们认为，高昂的价格、物流问题和潜在的治疗进展前景阻碍了血友病基因疗法的采用。CSL表示，推迟治疗可能会影响到一些符合条件的患者，这些患者原本计划在已上市的国家接受一次性治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL4T4051K5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","LU0170899867.USD","IE00B19Z3B42.SGD","BK7067","IE00B19Z3581.USD","BK4588","LU0321505439.SGD","LU0985481810.HKD","LU0306807586.USD","BK4533","IE00BLSP4239.USD","BK4585","BK4550","IE00BBT3K403.USD","BK4007","IE00BLSP4452.SGD","SGXZ57979304.SGD","BK4592","BK4568","BK4534","LU1057294990.SGD","LU0868494617.USD","SG9999001176.USD","LU1066053197.SGD","IE000M9KFDE8.USD","LU0289739699.SGD","SG9999002224.SGD","BK7501","LU0456855351.SGD","BK7508","LU0225771236.USD","LU1023059063.AUD","IE0002270589.USD","CSL.AU","LU0306806265.USD","LU0225284248.USD","LU0122379950.USD","SG9999011175.SGD","LU1883839398.USD","BK7511","LU0234572021.USD","SG9999002232.USD","LU0058720904.USD","SG9999003800.SGD","SG9999001176.SGD","BK4599","LU0321505868.SGD","BK4581","LU1894683264.USD","LU1894683348.USD","SG9999013999.USD"],"gpt_icon":0},{"id":"1128210509","title":"CSL有限公司正與監管機構協作制定策略 確保Hemgenix持續穩定供應","url":"https://stock-news.laohu8.com/highlight/detail?id=1128210509","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128210509?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 23:47","pubTimestamp":1773762439,"startTime":"0","endTime":"0","summary":"全球生物技术巨头CSL有限公司近日宣布，公司已启动与相关药品监管部门的密切沟通，共同探讨保障基因疗法Hemgenix长期稳定供应的战略方案。这一举措旨在应对潜在供应链挑战，确保这款突破性血友病B治疗药物能够持续满足全球患者的临床需求。通过建立多方协作机制，CSL将优化从原料采购到成品配送的全链条管理。此次战略合作凸显了CSL对患者用药可及性的长期承诺。CSL将通过技术创新与监管协作的双重路径，持续推动罕见病治疗领域的进步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7511","BK7067","CSL.AU"],"gpt_icon":0},{"id":"2620286284","title":"今日優惠-合併與收購","url":"https://stock-news.laohu8.com/highlight/detail?id=2620286284","media":"路透中文","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620286284?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 17:45","pubTimestamp":1773740741,"startTime":"0","endTime":"0","summary":"今日优惠-合并与收购路透3月17日 - 截至格林尼治标准时间周二9:30，报导了以下竞标、兼并、收购和处置情况：** Woolworths < WHLJ.J  > 说，它已同意收购私人控股的 in2food Holdings，收购金额未披露，这家食品和服装零售商的目标是更好地控制其优质方便食品的质量和供应。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL4T4050SH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGF.AU","BK4603","BK7112","PPM.AU","BK7160","AVXX","BK4187","BK7123","BK7501","WOW.AU","BK7511","BK1147","BK7040"],"gpt_icon":1},{"id":"1138284712","title":"CSL Seqirus將攜手長期合作伙伴Sinergium Biotech 供應差異化流感疫苗組合","url":"https://stock-news.laohu8.com/highlight/detail?id=1138284712","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138284712?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 23:02","pubTimestamp":1773154962,"startTime":"0","endTime":"0","summary":"CSL有限公司旗下业务单元CSL Seqirus宣布，将与其长期合作伙伴Sinergium Biotech合作，共同供应其差异化的流感疫苗产品组合。此次合作旨在进一步拓展相关市场的疫苗可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7511","BK7501","BK7067","CSL.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}